Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Mar 16, 2021

Une aide de 886 020 euros au titre du Contrat Innovation Région est attribuée pour le développement de ANT3310-MEM, un produit destiné à lutter contre les infections respiratoires acquises à l’hôpital. Labège, France, 16 Mars, 2021. Antabio SAS, société...

Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

May 6, 2020

Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem (MEM) and the novel broad-spectrum serine beta-lactamase inhibitor...

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

Jan 2, 2020

The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studie Labège, France, 2nd January 2020. Antabio SAS, the biopharmaceutical company focused on developing a broad pipeline of...

x

Jan 1, 2020

Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases 

x

Jan 1, 2020

Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases